Medindia
Medindia LOGIN REGISTER
Advertisement

Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment

Friday, August 25, 2017 Medico Legal News
Advertisement
- Protagonist granted Janssen worldwide rights to PTG-200, a first-in-class, oral peptide IL-23 receptor antagonist

Sponsored Post and Backlink Submission


Latest Press Release on Medico Legal News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close